SCHEMBL1733573

SCHEMBL1733573

COc1ccc(F)cc1-c1cc(C(N)=O)nc(N2CCCCC2)n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.62
ALDH1A1 P00352 7/20 0.62
HPGD P15428 6/20 0.62
GAA P10253 2/20 0.62
TP53 P04637 2/20 0.62
HSD17B10 Q99714 5/20 0.56
TSHR P16473 3/20 0.56
CASP1 P29466 2/20 0.56
CASP7 P55210 2/20 0.56
MAPT P10636 2/20 0.49
L3MBTL1 Q9Y468 2/20 0.49
ALOX15 P16050 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
USP2 O75604 1/20 0.46
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ATM Q13315 1/20 0.46
HTT P42858 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1733553 0.88 KDM4E (0.72) KDM4EALDH1A1HPGDGAATP53
SCHEMBL1734273 0.88 ALDH1A1 (0.65) KDM4EALDH1A1HPGDGAATP53
SCHEMBL1734583 0.87 ALDH1A1 (0.62) KDM4EALDH1A1HPGDGAATP53
SCHEMBL1733689 0.86 ALDH1A1 (0.61) KDM4EALDH1A1HPGDGAATP53
SCHEMBL3721073 0.86 AGER (0.49) KDM4EALDH1A1HPGDGAATP53
SCHEMBL1734377 0.85 ALDH1A1 (0.60) KDM4EALDH1A1HPGDGAATP53
SCHEMBL1734594 0.83 KDM4E (0.74) KDM4EALDH1A1HPGDGAATP53
SCHEMBL1734596 0.82 HPGD (0.77) KDM4EALDH1A1HPGDGAATP53
SCHEMBL1733464 0.78 KDM4E (0.70) KDM4EALDH1A1HPGDGAATP53
SCHEMBL1735696 0.77 KDM4E (0.61) KDM4EALDH1A1HPGDGAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US claimed
EP-1891018-B1 MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS VERTEX PHARMA (US) 2011-11-16 EP claimed
WO-2011131686-A1 A THERMALLY CONTROLLED ASSEMBLY NAPATECH A/S (DK) 2011-10-27 WO claimed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US claimed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-8822451-B2 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-09-02 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed
US-20070105833-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105833-A1 Modulators of ATP-binding cassette transporters ABCC4, CFTR, ABCC2 KDM4E 3910/4885ALDH1A1 2670/4885HPGD 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.